Novartis Cosentyx gains positive CHMP opinion for hidradenitis suppurativa

26.04.2023 - Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade Committee for Medicinal Products for Human Use (CHMP) opinion based on robust Phase III data showing Cosentyx (secukinumab) provided ... Seite 1

Related Keywords

Germany , Staedtisches Klinikum Dessau , Barry Mcgrath , Brandenburg Medical School , Drug Administration , European Medicines Agency , Committee For Medicinal Products Human Use , Novartis , European Hidradenitis Suppurativa Foundation , Medicinal Products , Human Use , Professor Christos , Founding Professor ,